News
BCAX
9.12
-2.77%
-0.26
Weekly Report: what happened at BCAX last week (1109-1113)?
Weekly Report · 3d ago
Bicara Therapeutics Earnings Call Highlights Trial Progress
TipRanks · 5d ago
Bicara Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 11/11 12:51
Bicara Therapeutics Price Target Cut to $36.00/Share From $42.00 by HC Wainwright & Co.
Dow Jones · 11/11 12:51
HC Wainwright & Co. Maintains Buy on Bicara Therapeutics, Lowers Price Target to $36
Benzinga · 11/11 12:40
Bicara Therapeutics price target lowered to $36 from $42 at H.C. Wainwright
TipRanks · 11/11 11:56
Bicara Therapeutics Is Maintained at Overweight by Morgan Stanley
Dow Jones · 11/10 17:11
Bicara Therapeutics Price Target Cut to $30.00/Share From $41.00 by Morgan Stanley
Dow Jones · 11/10 17:11
Bicara Therapeutics price target lowered to $43 from $45 at Stifel
TipRanks · 11/10 17:09
Morgan Stanley Maintains Overweight on Bicara Therapeutics, Lowers Price Target to $30
Benzinga · 11/10 17:01
Bicara Therapeutics management to meet virtually with BTIG
TipRanks · 11/10 16:49
Bicara Therapeutics price target lowered to $37 from $39 at BTIG
TipRanks · 11/10 16:49
Bicara Therapeutics Is Maintained at Buy by Stifel
Dow Jones · 11/10 14:30
Bicara Therapeutics Price Target Cut to $43.00/Share From $45.00 by Stifel
Dow Jones · 11/10 14:30
Stifel Maintains Buy on Bicara Therapeutics, Lowers Price Target to $43
Benzinga · 11/10 14:20
Analysts Are Bullish on These NA Stocks: Bicara Therapeutics Inc. (BCAX), Csquare, Inc. (CSQR)
TipRanks · 11/10 12:40
Analysts Offer Insights on NA Companies: Veradermics, Incorporated (MANE), Bicara Therapeutics Inc. (BCAX) and Exodus Movement, Inc. Class A (EXOD)
TipRanks · 11/10 11:40
Bank of America Securities Remains a Buy on Bicara Therapeutics Inc. (BCAX)
TipRanks · 11/10 11:05
Bicara Therapeutics Price Target Cut to $37.00/Share From $39.00 by BTIG
Dow Jones · 11/10 08:42
Bicara Therapeutics Is Maintained at Buy by BTIG
Dow Jones · 11/10 08:42
More
Webull provides a variety of real-time BCAX stock news. You can receive the latest news about Bicara Therapeutics through multiple platforms. This information may help you make smarter investment decisions.
About BCAX
Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Its lead program, ficerafusp alfa, is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor (EGFR), directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b). Through this dual-targeting mechanism, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation and the immunosuppressive TGF-b signaling within the tumor microenvironment. Ficerafusp alfa is initially being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need. Its platform is designed to facilitate the development of bifunctional therapies that precisely target the tumor and deliver a tumor-modulating payload to the tumor site.